PHILADELPHIA and LONDON Thomson Scientific has released the first issue of Movers and Shakers, a report analyzing the U.S. generics market from July to September 2007, as well as profiling some of the companies breaking into the market, and highlighting molecule patents currently being challenged.
Some of the highlights of the inaugural report were identifying key indicators of the industry like, abbreviated new drug applications and paragraph IV challenges. The report also released the names of some new companies entering the generics market like, Dabur India, who launched a paragraph IV challenge on the drug oxaliplatin, which is a drug used for chemotherapy and marketed under the brand name Eloxatin.
“Because of the dynamic nature of the generics market in the U.S., the common perception is that the market is relatively easy to break into,” said Kate Kuhrt, director, Generics and API Intelligence, Thomson Scientific. “However, our research has shown that there is huge competition between the incumbents and new companies vying for a slice of the market, and clearly there will be winners and losers. Ours is the first quarterly report to identify the real ‘movers and shakers’ within the generics market.”